Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Illumina in diabetes agreement with NIDDK, UVA
November 2007
SHARING OPTIONS:

SAN DIEGO—Illumina Inc. announced in mid October that it agreed to process more than 6,500 samples for researchers of the Type 1 Diabetes Genetics Consortium (T1DGC) via its FastTrack Genotyping Services. With financial support from the NIDDK, the T1DGC will attempt to identify genes that influence an individual's risk for developing type 1 diabetes. Principal Investigator Stephen Rich, Ph.D., from the University of Virginia and chair of the T1DGC steering committee, has chosen to use Illumina's recently launched HumanHap550-Duo BeadChip for the study.

 "The ultimate goal of this project is gene identification. Once these genes have been identified, researchers can then use this information to develop better approaches to detecting, treating, and preventing the disease," says Rich. 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.